{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T21:35:30Z","timestamp":1777152930015,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00845-4","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:53:37Z","timestamp":1761274417000},"page":"2625-2645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia\u2013Pacific"],"prefix":"10.1007","volume":"14","author":[{"given":"Thomas","family":"Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Kasahara-Kiritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keira","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-5792","authenticated-orcid":false,"given":"DaeYoung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva Lauretta","family":"Birija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Conyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara","family":"Ringland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"1","key":"845_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"key":"845_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10112235.","journal-title":"J Clin Med"},{"issue":"3","key":"845_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40120-024-00619-4","volume":"13","author":"NW Tsai","year":"2024","unstructured":"Tsai NW, Chien LN, Hung C, et al. Epidemiology, patient characteristics, and treatment patterns of myasthenia gravis in Taiwan: a population-based study. Neurol Ther. 2024;13(3):809\u201324. https:\/\/doi.org\/10.1007\/s40120-024-00619-4.","journal-title":"Neurol Ther"},{"key":"845_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health. 2020;5:100063. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100063.","journal-title":"Lancet Reg Health"},{"issue":"7_Supplement_1","key":"845_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208718","volume":"104","author":"K Grover","year":"2025","unstructured":"Grover K, Gandhi K, Cloutier M, et al. Real-world treatment patterns among patients with generalized myasthenia gravis (P6-11.027). Neurology. 2025;104(7_Supplement_1):1743. https:\/\/doi.org\/10.1212\/WNL.0000000000208718.","journal-title":"Neurology"},{"issue":"1","key":"845_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2022","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2022;12(1):107\u201328. https:\/\/doi.org\/10.1007\/s40120-022-00408-x.","journal-title":"Neurol Ther"},{"issue":"2","key":"845_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","volume":"102","author":"A Chaudhuri","year":"2009","unstructured":"Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009;102(2):97\u2013107. https:\/\/doi.org\/10.1093\/qjmed\/hcn152.","journal-title":"QJM"},{"key":"845_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11061597.","journal-title":"J Clin Med"},{"issue":"3","key":"845_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"845_CR10","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2147\/NDT.S374694","volume":"19","author":"T Vu","year":"2023","unstructured":"Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr. Ravulizumab in myasthenia gravis: a review of the current evidence. Neuropsychiatr Dis Treat. 2023;19:2639\u201355. https:\/\/doi.org\/10.2147\/NDT.S374694.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"845_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376. https:\/\/doi.org\/10.1007\/s40265-018-0875-9.","journal-title":"Drugs"},{"issue":"8","key":"845_CR12","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.4103\/1673-5374.363824","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637\u201344. https:\/\/doi.org\/10.4103\/1673-5374.363824.","journal-title":"Neural Regen Res"},{"key":"845_CR13","unstructured":"AstraZeneca. Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis. 2022."},{"key":"845_CR14","unstructured":"Argenx. Argenx announces VYVGART\u2122 approval in Japan for the treatment of generalized myasthenia gravis. 2022."},{"key":"845_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20064732","author":"T Adachi","year":"2023","unstructured":"Adachi T, El-Hattab AW, Jain R, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20064732.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"845_CR16","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011.","journal-title":"Clin Ther"},{"key":"845_CR17","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296","volume":"27","author":"S Johnson","year":"2021","unstructured":"Johnson S, Katyal N, Narula N, Govindarajan R. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. Med Sci Monit. 2021;27:e933296. https:\/\/doi.org\/10.12659\/MSM.933296.","journal-title":"Med Sci Monit"},{"key":"845_CR18","doi-asserted-by":"publisher","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","volume":"14","author":"KJ Herr","year":"2023","unstructured":"Herr KJ, Shen SP, Liu Y, Yang CC, Tang CH. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan. Front Neurol. 2023;14:1203679. https:\/\/doi.org\/10.3389\/fneur.2023.1203679.","journal-title":"Front Neurol"},{"issue":"7","key":"845_CR19","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","volume":"45","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, Iacono S, Militello M, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci. 2024;45(7):3481\u201394. https:\/\/doi.org\/10.1007\/s10072-024-07368-0.","journal-title":"Neurol Sci"},{"issue":"39","key":"845_CR20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e242","volume":"36","author":"S Jeong","year":"2021","unstructured":"Jeong S, Noh Y, Oh IS, Hong YH, Shin JY. Survival, prognosis, and clinical feature of refractory myasthenia gravis: a 15-year nationwide cohort study. J Korean Med Sci. 2021;36(39):e242. https:\/\/doi.org\/10.3346\/jkms.2021.36.e242.","journal-title":"J Korean Med Sci"},{"issue":"11","key":"845_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"845_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"845_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380. https:\/\/doi.org\/10.2147\/DMSO.S120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"845_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"845_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16.","journal-title":"Neurology"},{"key":"845_CR26","unstructured":"European Pharmaceutical Market Research Association (EPhMRA): Code of Conduct. 2022. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed 04 July 2025."},{"key":"845_CR27","unstructured":"US Department of Health and Human Services: Summary of the HIPAA Privacy Rule. 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 04 July 2025."},{"key":"845_CR28","unstructured":"Health Information Technology (HITECH): Health Information Technology Act. 2009. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 04 July 2025."},{"key":"845_CR29","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"845_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-023-02727-0","volume":"18","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, DeCourcy J, et al. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey. Orphanet J Rare Dis. 2023;18(1):169. https:\/\/doi.org\/10.1186\/s13023-023-02727-0.","journal-title":"Orphanet J Rare Dis"},{"key":"845_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00796-w","author":"R Mantegazza","year":"2025","unstructured":"Mantegazza R, Antonini G, Gastaldi M, et al. Use of corticosteroids in myasthenia gravis: expert opinion for daily management. Neurol Ther. 2025. https:\/\/doi.org\/10.1007\/s40120-025-00796-w.","journal-title":"Neurol Ther"},{"issue":"1","key":"845_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","volume":"14","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Masuda M, Uzawa A, et al. Japan MG registry: chronological surveys over 10\u00a0years. Clin Exp Neuroimmunol. 2022;14(1):5\u201312. https:\/\/doi.org\/10.1111\/cen3.12731.","journal-title":"Clin Exp Neuroimmunol"},{"key":"845_CR33","doi-asserted-by":"publisher","first-page":"1339167","DOI":"10.3389\/fneur.2024.1339167","volume":"15","author":"Y Ye","year":"2024","unstructured":"Ye Y, Murdock DJ, Chen C, Liedtke W, Knox CA. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024;15:1339167. https:\/\/doi.org\/10.3389\/fneur.2024.1339167.","journal-title":"Front Neurol"},{"issue":"10","key":"845_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2023-333097","volume":"95","author":"J Vissing","year":"2024","unstructured":"Vissing J, Atula S, Savolainen M, et al. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry. 2024;95(10):919\u201326. https:\/\/doi.org\/10.1136\/jnnp-2023-333097.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"845_CR35","doi-asserted-by":"publisher","first-page":"175628642412374","DOI":"10.1177\/17562864241237495","volume":"17","author":"J van Enkhuizen","year":"2024","unstructured":"van Enkhuizen J, Binns J, Betts A, et al. A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England. Ther Adv Neurol Disord. 2024;17:17562864241237496. https:\/\/doi.org\/10.1177\/17562864241237495.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"845_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12883-024-03869-9","volume":"24","author":"J Pesa","year":"2024","unstructured":"Pesa J, Choudhry Z, de Courcy J, et al. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries. BMC Neurol. 2024;24(1):385. https:\/\/doi.org\/10.1186\/s12883-024-03869-9.","journal-title":"BMC Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:16Z","timestamp":1763376316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00845-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sophie Barlow, Shiva Lauretta Birija, Joe Conyers, Hannah Connolly, and Gregor Gibson are employees of Adelphi Real World. Niall Hatchell is a former employee of Adelphi Real Word and a current employee of IQVIA. Ciara Ringland is a former employee of Adelphi Real World and a current employee of Vitaccess. Thomas Webb, Keira Herr, DaeYoung Yu, Mami Kasahara-Kiritani and Bolam Lee are employees of Johnson & Johnson group of companies and own Johnson & Johnson shares as part of employment remuneration. Yoon Ho Hong received research grants from the National Research Foundation of Korea, and received consultation fees from Biogen, Janssen, Merck, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data collection was undertaken in line with European Pharmaceutical Marketing Research Association (EphMRA) guidelines [\n                      \n                      ]. Exemption from ethics approval was sought and granted from Pearl IRB (IRB; study number is AG9525). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Helsinki Declaration of 1964 (and its later amendments), the US Health Insurance Portability and Accountability Act 1996 [\n                      \n                      ], and Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ]. All authors from Johnson & Johnson had permission to access the Adelphi Real World gMG DSP dataset through the subscription purchased by Johnson & Johnson. Other authors include employees of Adelphi Real World, the dataset owner.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}